Human Umbilical Cord Mesenchymal Stem Cell-derived Treatment of Severe Pulmonary Arterial Hypertension

Overview

Journal Nat Cardiovasc Res

Publisher Springer Nature

Specialty Cardiology & Vascular Diseases

Date 2024 Aug 28

PMID 39195868

Authors

Georg Hansmann

Philippe Chouvarine

Franziska Diekmann

Martin Giera

Markus Ralser

Michael Mulleder

Constantin von Kaisenberg

Harald Bertram

Ekaterina Legchenko

Ralf Hass

Affiliations

Soon will be listed here.

Abstract

Here we report application of human umbilical cord mesenchymal stem cell (HUCMSC)-derived therapy for pulmonary arterial hypertension (PAH). A 3-year-old female presented with heritable PAH associated with hereditary hemorrhagic telangiectasia and was treated for 6 months with serial intravascular infusions of conditioned media (CM) from allogenic HUCMSCs. The treatment markedly improved clinical and hemodynamic parameters and decreased blood plasma markers of vascular fibrosis, injury and inflammation. A comparative analysis of single-cell RNA sequencing data collected from three HUCMSCs and two human umbilical vein endothelial cell (HUVEC) controls identified eight common cell clusters, all of which indicated regenerative potential specific for HUCMSCs. The properties of HUCMSCs were validated by untargeted label-free quantitation of the cell and CM proteome, suggesting increased activity of regeneration, autophagy and anti-inflammation pathways and mitochondrial function. Prostaglandin analysis demonstrated increased HUCMSC secretion of prostaglandin E2, known for its regenerative capacity. Additional prospective clinical studies are warranted to confirm and further explore the benefits of HUCMSC-derived therapy for PAH.

Citing Articles

A prospective randomized controlled study of multi-intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure and reduced ejection fraction (PRIME-HFrEF) trial: Rationale and design.

Gong X, Jiao Y, Hu H, Zhang R, Jia W, Zhao J Contemp Clin Trials Commun. 2024; 41:101350.

PMID: 39246626 PMC: 11377133. DOI: 10.1016/j.conctc.2024.101350.

Can Mesenchymal Stem Cell-Derived Therapeutics Protect the Developing Brain During Cardiac Surgery?.

Hansmann G JACC Basic Transl Sci. 2024; 8(12):1536-1538.

PMID: 38205354 PMC: 10774766. DOI: 10.1016/j.jacbts.2023.08.012.

Extracellular vesicles modulate key signalling pathways in refractory wound healing.

Yang B, Lin Y, Huang Y, Zhu N, Shen Y Burns Trauma. 2023; 11:tkad039.

PMID: 38026441 PMC: 10654481. DOI: 10.1093/burnst/tkad039.

Pulmonary Hypertension: A Contemporary Review.

Johnson S, Sommer N, Cox-Flaherty K, Weissmann N, Ventetuolo C, Maron B Am J Respir Crit Care Med. 2023; 208(5):528-548.

PMID: 37450768 PMC: 10492255. DOI: 10.1164/rccm.202302-0327SO.

Mesenchymal stem cell secretome-loaded fibrin glue improves the healing of intestinal anastomosis.

Yu W, Zhou H, Feng X, Liang X, Wei D, Xia T Front Bioeng Biotechnol. 2023; 11:1103709.

PMID: 37064233 PMC: 10102583. DOI: 10.3389/fbioe.2023.1103709.

References

Nakamura M, Liu T, Husain S, Zhai P, Warren J, Hsu C . Glycogen Synthase Kinase-3α Promotes Fatty Acid Uptake and Lipotoxic Cardiomyopathy. Cell Metab. 2019; 29(5):1119-1134.e12. PMC: 6677269. DOI: 10.1016/j.cmet.2019.01.005. View

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

Best D, Vaughn C, McDonald J, Damjanovich K, Runo J, Chibuk J . Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patients. J Med Genet. 2011; 48(5):358-60. DOI: 10.1136/jmg.2010.088286. View

Iablonskii P, Carlens J, Mueller C, Aburahma K, Niehaus A, Boethig D . Indications and outcome after lung transplantation in children under 12 years of age: A 16-year single center experience. J Heart Lung Transplant. 2021; 41(2):226-236. DOI: 10.1016/j.healun.2021.10.012. View

Galie N, Channick R, Frantz R, Grunig E, Jing Z, Moiseeva O . Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2018; 53(1). PMC: 6351343. DOI: 10.1183/13993003.01889-2018. View

Calvier L, Chouvarine P, Legchenko E, Hoffmann N, Geldner J, Borchert P . PPARγ Links BMP2 and TGFβ1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism. Cell Metab. 2017; 25(5):1118-1134.e7. DOI: 10.1016/j.cmet.2017.03.011. View

Shah R, Patel T, Freedman J . Circulating Extracellular Vesicles in Human Disease. N Engl J Med. 2018; 379(22):2180-2181. DOI: 10.1056/NEJMc1813170. View

Shovlin C, Guttmacher A, Buscarini E, Faughnan M, Hyland R, Westermann C . Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000; 91(1):66-7. DOI: 10.1002/(sici)1096-8628(20000306)91:1<66::aid-ajmg12>3.0.co;2-p. View

Lavrentieva A, Majore I, Kasper C, Hass R . Effects of hypoxic culture conditions on umbilical cord-derived human mesenchymal stem cells. Cell Commun Signal. 2010; 8:18. PMC: 2918620. DOI: 10.1186/1478-811X-8-18. View

10.

North T, Goessling W, Walkley C, Lengerke C, Kopani K, Lord A . Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007; 447(7147):1007-11. PMC: 2775137. DOI: 10.1038/nature05883. View

11.

Faughnan M, Palda V, Garcia-Tsao G, Geisthoff U, McDonald J, Proctor D . International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2009; 48(2):73-87. DOI: 10.1136/jmg.2009.069013. View

12.

Pfarr N, Fischer C, Ehlken N, Becker-Grunig T, Lopez-Gonzalez V, Gorenflo M . Hemodynamic and genetic analysis in children with idiopathic, heritable, and congenital heart disease associated pulmonary arterial hypertension. Respir Res. 2013; 14:3. PMC: 3547748. DOI: 10.1186/1465-9921-14-3. View

13.

Morrell N, Aldred M, Chung W, Elliott C, Nichols W, Soubrier F . Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2018; 53(1). PMC: 6351337. DOI: 10.1183/13993003.01899-2018. View

14.

Calvier L, Boucher P, Herz J, Hansmann G . LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARγ Activation. Circ Res. 2019; 124(12):1778-1785. PMC: 6554044. DOI: 10.1161/CIRCRESAHA.119.315088. View

15.

Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jais X . Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med. 2010; 181(8):851-61. DOI: 10.1164/rccm.200908-1284OC. View

16.

Trembath R, Thomson J, Machado R, Morgan N, Atkinson C, Winship I . Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001; 345(5):325-34. DOI: 10.1056/NEJM200108023450503. View

17.

Klinger J, Pereira M, Del Tatto M, Brodsky A, Wu K, Dooner M . Mesenchymal Stem Cell Extracellular Vesicles Reverse Sugen/Hypoxia Pulmonary Hypertension in Rats. Am J Respir Cell Mol Biol. 2019; 62(5):577-587. PMC: 7193796. DOI: 10.1165/rcmb.2019-0154OC. View

18.

Muller T, Kalxdorf M, Longuespee R, Kazdal D, Stenzinger A, Krijgsveld J . Automated sample preparation with SP3 for low-input clinical proteomics. Mol Syst Biol. 2020; 16(1):e9111. PMC: 6966100. DOI: 10.15252/msb.20199111. View

19.

Willis G, Fernandez-Gonzalez A, Anastas J, Vitali S, Liu X, Ericsson M . Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation. Am J Respir Crit Care Med. 2017; 197(1):104-116. PMC: 5765387. DOI: 10.1164/rccm.201705-0925OC. View

20.

Tsaousi A, Williams H, Lyon C, Taylor V, Swain A, Johnson J . Wnt4/β-catenin signaling induces VSMC proliferation and is associated with intimal thickening. Circ Res. 2011; 108(4):427-36. DOI: 10.1161/CIRCRESAHA.110.233999. View